Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to ...
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...